GlassScriptPhysician profile
Melody Badii
NPI 1578050795
$2,628.14
in general payments reported to CMS, 2019-2025
14 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.71 · 2022: $633 · 2023: $88.60 · 2024: $1,623 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,050 · Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,050.00 |
| Food and Beverage | $903.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,050.00 | 2024 | |
| Ucb, INC. | $332.99 | 2024 | Rystiggo, Zilbrysq |
| Amgen INC. | $259.63 | 2022-2025 | Uplizna |
| Argenx US, INC. | $245.73 | 2022-2024 | Vyvgart |
| Alnylam Pharmaceuticals INC. | $122.37 | 2024 | Amvuttra |
| Genzyme Corporation | $104.13 | 2022 | |
| Csl Behring | $99.69 | 2022-2023 | Hizentra |
| Life Molecular Imaging LTD | $90.57 | 2025 | Neuraceq |
| Genentech USA, INC. | $89.58 | 2022 | |
| Abbvie INC. | $71.19 | 2022 | |
| Biogen, INC. | $68.39 | 2022 | |
| Pfizer INC. | $41.71 | 2021 | |
| Tanabe Pharma America, INC. | $28.03 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $24.13 | 2023 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melody Badii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.